Common Stock, $0.001 par value
- Symbol
- VIVS
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 1.01, 9.01 · 8-K
VivoSim Labs, Inc.
VIVSNASDAQEQUITYCurrent
Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On October 13, 2026, Organovo, Inc. (“Organovo”), a wholly-owned subsidiary of VivoSim Labs, Inc. (the “Company”), entered into a Second Amendment to Amended and Restated Lease (the “Amendment”) with San Diego Inspire 2, LLC (the “Landlord”).…
Company context
We are a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. We offer partners liver and intestinal toxicology insights using our new approach methodologies (“NAM”) models. We anticipate accelerated adoption of human tissue models following the U.S. Food and Drug Administration (“FDA”) announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. We also expect to offer bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of these complex human tissue models.
Current securities
Historical securities (1)
Recent company filings
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security HoldersOct 6, 2026
- 4 filingSep 1, 2026
- ARS filingAug 21, 2026
- Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingAug 21, 2026
- DEF 14A filingAug 21, 2026
Registered securities in this filing
VivoSim Labs, Inc. · 8-K · Filed 2026-10-16
Disclosure sections
Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement.
On October 13, 2026, Organovo, Inc. (“Organovo”), a wholly-owned subsidiary of VivoSim Labs, Inc. (the “Company”), entered into a Second Amendment to Amended and Restated Lease (the “Amendment”) with San Diego Inspire 2, LLC (the “Landlord”). The Amendment amends that certain Amended and Restated Lease between Organovo and the Landlord, dated November 23, 2020, as amended by the First Amendment to Amended and Restated Lease, dated November 17, 2021 (as so amended, the “Lease”) relating to the lease of the Company’s principal executive offices located at 11555 Sorrento Valley Road, San Diego, CA 92121 to, among other things: (i) reduce the leased premises by requiring the Company to vacate and surrender Suite 202 on or before February 28, 2027; (ii) extend the term with respect to Suite 100 from March 1, 2027 through April 30, 2028; (iii) adjust the monthly base rent to $43,072.85; (iv) provide that the Company will receive a rental abatement for the period from March 1, 2027 through June 30, 2027 of $21,536.43 per month, for an aggregate rental abatement of $86,145.70; and (v) modify certain other terms and provisions of the Lease.
The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full and complete terms of the Amendment, a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.